key: cord-0320182-75qb9lts
authors: Chatterjee, Maitrayee; Huang, Liane Z.X.; Wang, Chunyan; Mykytyn, Anna Z.; Westendorp, Bart; Wubbolts, Richard W.; Bosch, Berend-Jan; Haagmans, Bart L.; van Putten, Jos P.M.; Strijbis, Karin
title: The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
date: 2021-10-29
journal: bioRxiv
DOI: 10.1101/2021.10.29.466408
sha: f3e9baa8698427a6863d7b83a5f7ac010c9732e9
doc_id: 320182
cord_uid: 75qb9lts

Mucins play an essential role in protecting the respiratory tract against microbial infections. The heavily O-glycosylated gel-forming mucins MUC5AC and MUC5B eliminate pathogens by mucociliary clearance while transmembrane mucins MUC1, MUC4, and MUC16 restrict microbial invasion at the apical surface of the epithelium. In this study, we determined the impact of host mucins and mucin glycans on SARS-CoV-2 spike-mediated epithelial entry. Human lung epithelial Calu-3 cells have endogenous expression of the SARS-CoV-2 entry receptor ACE2 and express high levels of glycosylated MUC1 on the surface but not MUC4 and MUC16. Removal of the MUC1 extracellular domain (ED) using the O-glycan-specific mucinase StcE greatly enhanced spike binding and viral infection. By contrast, removal of mucin glycans sialic acid and fucose did not impact viral invasion. This study implicates the glycosylated ED of MUC1 as an important component of the host defense that restricts the severity of SARS-CoV-2 infection.

During entry through the respiratory system, pathogens encounter a defensive mucus system that protects the underlying epithelium. The major components of mucus are heavily O-glycosylated mucin glycoproteins. Soluble mucins are secreted by Goblet cells and provide mucus threads for mucociliary clearance (MCC) of particles and pathogens. Transmembrane mucins are expressed on the apical membrane and cilia and prevent access to epithelial surface receptors 1 . SARS-CoV-2, the coronavirus that is responsible for the COVID-19 pandemic, is an enveloped, single-stranded, positive-sense RNA virus that belong to the β coronavirus genus within the Coronaviridae family 2,3 . SARS-CoV-2 preferentially utilizes receptorangiotensin-converting enzyme 2 (ACE2) as entry receptor by interaction with its envelope-anchored spike (S) protein 4 . In addition to ACE2, SARS-CoV-2 entry requires proteolytic cleavage of the spike protein that can be mediated by the transmembrane serine protease 2 (TMPRSS2) 5 . Human coronaviruses have also been described to depend on sialic acids linked to glycoproteins or gangliosides as primary attachment sites in the respiratory tract 6 .

Glycosylated mucins can be decorated with sialic acids, but the role of mucin glycans and specific mucins during SARS-CoV-2 entry remains to be established.

The major mucins of the respiratory system are soluble mucins MUC5AC and MUC5B, and transmembrane (TM) mucins MUC1, MUC4, and MUC16 1 . MUC1 and MUC4 are expressed in the upper and lower airway epithelium, whereas MUC16 expression is restricted to the lower airways 7 .

The high molecular weight mucin glycoproteins contain domains with extensive O-glycan structures that often terminate with charged sialic acids or hydrophobic fucoses that impact their interaction with microbes 8 . The expression and glycosylation profiles of mucins are directly influenced by colonization and invasion by bacteria and viruses and are altered during inflammation of the respiratory tract 9 . Transmembrane mucins form filamentous structures that extend above the apical surface of the epithelium and these mucins consist of a heavily O-glycosylated N-terminal extracellular domain (ED), a single transmembrane domain, and a C-terminal cytoplasmic domain (CT) with signaling capacity. In the lung, MUC1 primarily expresses around microvilli and protrudes at least 100 nm from the cell surface whereas MUC4 (∼300 nm in size), and the even larger MUC16 are expressed on the surface of cilia 10 . Together, the TM mucins form a barrier that restricts access to the underlying epithelium, act as releasable decoy receptors, and sterically hinder the binding of pathogens to underlying cellular receptors 11 . MUC1 has been most extensively studied and implicated in defense against respiratory infections with Pseudomonas aeruginosa 12 and respiratory syncytial virus 13 and Influenza A virus infection 14 . In this present study, we determined the impact of transmembrane mucins on spike-mediated entry of SARS-CoV-2 in human respiratory cells. MUC1 is the dominant transmembrane mucins and removal of the extracellular domain greatly enhances spike binding and viral infection. This study points to critical importance of MUC1 in limiting SARS-CoV-2 infection.

The Human Cell Atlas consortium respiratory single cell RNA-seq dataset allows analysis of gene expression in the nasal cavity and proximal, intermediate, and distal respiratory tract 15 . We analysed this dataset to determine the expression of ACE2 and mucins in different respiratory cell types present in the upper and lower respiratory mucosa. ACE2-positive cells included secretory, basal, suprabasal and multiciliated cells and the majority of secretory and multiciliated cells expressed MUC1 ( Fig 1A) .

Next, we determined which mucins are most highly expressed in ACE2-positive cells in the respiratory tract. The most highly expressed TM mucin in ACE2-positive cells was MUC1 followed by TM mucins MUC4 and MUC16 and soluble mucins MUC5AC and MUC5B ( Fig 1B) . This analysis suggests that the TM mucin MUC1 is the dominant mucin in ACE2-positive respiratory cells in healthy individuals.

Human respiratory Calu-3 cells have high expression of ACE2 and TMPRSS2 and are highly susceptible to SARS-CoV-2 spike-mediated entry 16, 17, 5 . We first determined the expression of different mucins and their glycans on Calu-3 cells by immunofluorescence confocal microscopy. Multiple Z-stack images were collected which showed expression of MUC1, MUC4, and MUC5AC and only very limited expression of MUC16 (Fig 1C, S1A respectively) . To distinguish which mucins are expressed on the extracellular surface, we performed immunofluorescence staining without permeabilization of the Calu-3 cells. Using this method, MUC1 was clearly detectable on the surface whereas MUC4 and MUC5AC could not be stained indicating an intracellular localization ( Fig 1D) . Next, we determined the expression of the terminal mucin glycans sialic acid and fucose on Calu-3 cells. Immunofluorescence with SNA, MALII, and UEA-I lectin showed the presence of α-2,6 sialic acid, α-2,3 sialic acid, and fucose on Calu-3 cells, respectively ( Fig 1E) . The α-2,6 sialic acid and α-2,3 sialic acid signals (SNA and MALII) were more prominently detected at the edge of the cell island compared to the fucose signal (UEA1) and some colocalization with MUC1 could be observed. These results demonstrate that Calu-3 cells endogenously express MUC1 on their surface and have abundant expression of sialic acids and fucose.

The StcE mucinase recognizes an O-glycosylated serine-threonine motif that is abundant in mucins and is virtually absent in non-mucin proteins 18 . We previously applied this bacterial mucinase and its inactive point mutant E447D to remove the MUC1 ED 19 . To investigate the effect of StcE on endogenous MUC1 expressed by Calu-3 cells, confocal microscopy was performed on non-treated, StcE-treated and E447D-treated Calu-3 cells and stained with α-MUC1-ED antibody 214D4, α-MUC1-SEA antibody 232A1, and α-MUC1-CT antibody CT2. StcE treatment efficiently removed the glycosylated part of the MUC1 extracellular domain as indicated by a complete loss of α-MUC1-ED 214D4 staining after incubation with the enzyme (Fig 2A) . The MUC1 SEA domain and CT are predicted not to be digested by StcE and indeed both domains remained detectable after enzyme treatment ( Fig   2B, 2C) . We next investigated the effect of StcE, E447D, neuraminidase, and fucosidase treatment on MUC1 by Western blot. Calu-3 cells were incubated with the enzymes for 3 h and then subjected to Western blot analysis with the α-MUC1-ED antibody 214D4 and α-MUC1-CT antibody CT2. After incubation with StcE, the glycosylated part of the extracellular domain of MUC1 (about 450 kDa) was no longer detectable. The high molecular weight MUC1 band was not affected by treatment with the inactive enzyme E447D or fucosidase. After neuraminidase treatment on the other hand, we did observe a reduction of the MUC1 signal which could be caused by a change in antibody recognition or altered protein transfer to the membrane ( Fig 2D) . The observed banding pattern for the MUC1 cytoplasmic tail was not affected by the enzymatic treatments ( Fig 2E) . Furthermore, we wanted to determine the effect of enzymatic treatment on ACE2 stability because the ACE2 receptor itself is glycosylated 20 . No change in expression of the full-length glycosylated ACE2 (nearly 140 kDa) could be observed after treatment with StcE, E447D, neuraminidase, or fucosidase. Interestingly, the soluble form of ACE2 (around 70 kDa) was more prominently detectable after fucosidase treatment ( Fig 2F) .

These results demonstrate that StcE cleaves the glycosylated part of the MUC1 ED without affecting ACE2 expression in Calu-3 cells.

MUC1 is heavily decorated with O-glycans. To investigate whether these individual glycans or glycosylated ED of MUC1 form a barrier against SARS-CoV-2, we removed O-glycan sugars using neuraminidase, fucosidase and StcE was used to cleave the MUC1 ED. Surface α2,3-, α2,6-, and α2,8linked sialic acids were removed by incubation with neuraminidase and fucose by fucosidase treatment. Neuraminidase treatment for 3 h removed the majority of surface-exposed α2,3-linked sialic acids as detected by MAL-II staining, and α2,6-linked sialic acids detected by SNA staining (S1B).

Similarly, fucosidase treatment for 3 h cleaved surface-exposed fucose which was detected by UEA1 staining (S1C). StcE treatment effectively removed the MUC1 glycosylated ED from the cellular surface as describe above (Fig 2) . After enzymatic treatment of the Calu-3 cells, a SARS-CoV-2 pseudotyped virus carrying the spike protein and encoding a GFP reporter (SARS2-S pseudotyped VSV-GFP) was added in the absence or presence of an anti-spike monoclonal antibody and incubated for 24 hours.

StcE treatment greatly enhanced the number of SARS2-S pseudotyped VSV-GFP positive cells, while E447D-treated cells did not show enhanced viral entry. No obvious change in viral infection could be observed after neuraminidase or fucosidase treatment ( Fig 3A) . In all experimental conditions, viral infection was completely blocked in the presence of the monoclonal antibody against the SARS-CoV-2 spike protein demonstrating that we are looking at spike-mediated entry in our experimental setup.

The GFP signal was quantified using ImageJ showing a significant 5.4-fold increase in Calu-3 virus infection after StcE treatment and no significant difference after neuraminidase and fucosidase treatment ( Fig 3B) .

In an independent set of experiments with a luciferase pseudovirus (SARS2-S pseudotyped VSV-Luc), we also observed a 4-fold increase in viral infection after StcE treatment ( Fig 3C) . As an additional control, we performed the infection with an VSV-G pseudotyped VSV-Luc that lacks the spike protein.

We observed enhanced entry of VSV-G pseudotyped VSV-Luc into Calu-3 after StcE and neuraminidase treatment whereas fucosidase treatment had an opposite effect. As expected, the infection could not be blocked with the mAb against spike ( Fig 3D) .

Next, we investigated the effect of mucin removal on infection with the authentic SARS-CoV-2 virus.

presence of an anti-spike monoclonal antibody for 8 hours to study initial entry. In line with our pseudovirus experiments, we observed a significant increase in the number of infected cells when cells were treated with StcE mucinase in comparison to control. Again, neuraminidase and fucosidase treatment did not significantly impact viral infection albeit we observed a trend towards increased infection after neuraminidase treatment (Fig 3E) .

To understand the spatial relationship between the ACE2 receptor and the MUC1 transmembrane mucin, we performed confocal microscopy on Calu-3 cells stained for ACE2 receptor and the MUC1 extracellular domain. ACE2 signal was observed as scattered puncta across the monolayer and a few bright dome-like structures (Fig 3F, G) . Both staining types were also visible in StcE and E447D-treated cells (Fig S2A-D) . StcE treatment resulted in a complete loss of MUC1-ED staining but did not visibly alter expression levels or subcellular localization of ACE2 (Fig S2A, B) . Interestingly, in the dome-like structures we observed a clear layer of MUC1 above the ACE2 signal, possibly indicative of a protective function of the MUC1 glycosylated ED (Fig 3G, side view) . Confocal microscopy on Calu-3 cells infected with SARS2-S pseudotyped VSV-GFP confirmed that StcE treatment increased the number of infected cells (Fig 3H) . Together these data demonstrate that removal of the MUC1 glycosylated ED results in increased SARS-CoV-2 infection of lung epithelial cells without affecting ACE2 expression. No effect on viral entry was observed after removing individual glycans sialic acid and fucose.

Negatively charged molecules such as sialic acid or heparan sulphate (HS) on the cellular surface or extracellular matrix proteoglycans have been described to facilitate viral entry 21, 22 . Therefore, we investigated if heparanase treatment to remove HS or neuraminidase treatment to remove sialic acids impacted viral invasion after removal of the MUC1 glycosylated domain with StcE. Calu-3 cells were first treated with StcE, followed by treatment with heparanase or neuraminidase and subsequent viral infection with SARS2-S pseudotyped VSV-Luc. Confocal microscopy confirmed the removal of HS and α-2,6 sialic acid from the surface of Calu-3 cells after heparanase and neuraminidase treatment, respectively (Fig S2A, B) . Quantification of viral infection showed that the combination treatments did not significantly impact viral invasion compared to StcE only condition (Fig S3C) . A small reduction of viral infection was observed when the cells were treated with only heparanase in comparison to the control cells without treatment. All infections in this experiment could be blocked by the mAb demonstrating spike-mediated infection. This result suggests that SARS-CoV-2 entry does not depend on these negatively charged molecules on the cell surface of Calu-3 cells.

In a final set of experiments, we investigated if removal of the MUC1 ED directly affected spike and virus attachment to the cellular surface. Calu-3 cells were treated with StcE followed by incubation with purified Fc tagged spike protein (SARS2-S1B-Fc) or SARS2-S pseudotyped VSV-GFP for 1 h at 4°C to monitor attachment and prevent entry. The spike protein was stained without first permeabilizing the prevent detection of intracellular spike. In untreated and E447D-treated cells, spike binding was observed in patches along the edge of the cell island while cells treated with StcE showed extensive staining (Fig 4A) . Quantification of the fluorescent spike signal on the edges of the cell islands using ImageJ confirmed a significant increase in StcE-treated cells raw as determined by integrated density/length (sum of all pixels/µm) (Fig 4B) . In line with these findings, also more SARS2-S pseudotyped VSV-GFP virus was able to attach to Calu-3 cells after StcE treatment (Fig 4C) . Together these results show that enzymatic removal of the MUC1 extracellular domain allows more virus attachment to cells and thus increases infectivity.

The mucosal barrier is the body's first line of defense and offers protection from infection by pathogens. However, mucins can also serve as attachment sites for bacterial and viral pathogens. The findings presented in this study demonstrate that the transmembrane mucin MUC1 plays a substantial protective role during SARS-CoV-2 infection at the respiratory surface. We show that MUC1 is the dominant mucin in ACE2-positive cells in the respiratory epithelium and that human lung epithelial Calu-3 cells expressed high levels of MUC1, while TM mucins MUC4 and MUC16 and secreted mucin MUC5AC were barely detectable (Fig 1, 2) . In various SARS-CoV-2 infection studies, we demonstrate that the large MUC1 glycoprotein forms a protective layer that prevents access of the virus to the underlying ACE2 receptor (Fig 3) . Our experiments indicate that enzymatic removal of the extracellular domain of MUC1 enhances viral infection of lung epithelial cells (Fig 3) . In the absence of the MUC1 glycosylated domain, increased binding of purified spike protein and virus to the cellular surface was observed (Fig 4) .

There is growing evidence for the protective role of soluble and transmembrane mucins during SARS-CoV-2 infection. In the course of COVID-19, elevated levels of gel-forming MUC5AC and shed MUC1 can be detected in sputum aspirated from the trachea of patients 23 . The MUC5B genetic variant rs35705950 is associated with higher expression of the soluble mucin MUC5B, is underrepresented in COVID-19 patients compared to healthy individuals, suggesting a protective role for MUC5B 24 . It cannot be excluded that decreased mucus production and weakened MCC contribute to the higher susceptibility of SARS-CoV-2 in aged individuals 25 interact and/or are in the same protein complex on the respiratory surface 28 . Our data indicate that steric hindrance of the large glycosylated extracellular domain of MUC1 prevents the virus from reaching the ACE2 receptor (Fig 5) . This is in line with a recent study that used mucin mimetics glycopolymers that were capable of shielding surface receptors 29 . In a previous study, we have shown that MUC1 ED alters the cell membrane to tubulated morphology and reduce β1-integrin-mediated bacterial invasion 19 . In the present study, we have not observed any influence of MUC1 ED on membrane architecture. Different studies describe that for viral entry SARS-CoV-2 benefits from negatively charged residues like sialic acid-containing glycans or membrane glycosaminoglycans such as heparan sulfate proteoglycans on the cell surface 30, 31, 32, 33 . In contrast with this findings, neuraminidase treatment of Calu-3 cells modestly increased SARS-CoV-2 infection 34 

The pseudotyped vesicular stomatitis virus (VSV) was produced by using the protocol of Whitt 43 . The detailed protocol of the production of pseudotyped VSV, SARS2-Spike pseudotyped VSV virus and virus neutralization assay is described in the supplementary methods. The optimal working concentration of SARS2-Spike pseudotyped VSV particles (SARS2-S pseudotyped VSV-GFP and SARS2-S pseudotyped VSV-Luc) was determined by viral titration assay on Calu-3 cells.

SARS-CoV-2 (isolate BetaCoV/Munich/BavPat1/2020; European Virus Archive Global #026V-03883;

kindly provided by Dr. C. Drosten) was propagated on Calu-3 cells in OptiMEM I (1X) + GlutaMAX (Gibco), supplemented with penicillin (100 IU/mL) and streptomycin (100 IU/mL) at 37°C in a humidified CO2 incubator. Stocks were produced as described previously 44 . A detailed description of virus production can be found in the supplementary methods.

StcE and StcE-E447D were expressed and purified as described previously 19 . For mucinase treatment, 

For infection experiments, Calu-3 cells were grown in 96-well plates and allowed to reach around 90%

confluency. Then, cells were treated with enzymes for 3 h at 37°C and 5% CO2, before they were 

Cells were grown on coverslips up to 80% confluency were analyzed by immunofluorescent staining.

Cells were washed twice with DPBS and fixed with 4% paraformaldehyde in PBS (Affymetrix) for 20 min at room temperature and fixation was stopped with 50 mM NH4Cl in PBS for 10 min. The staining procedure and antibody details are described in the supplementary methods.

Calu-3 cells were grown in 6-well plates for 7 days before enzyme treatment. Enzyme-treated cells were washed thrice with cold DPBS and collected with a scraper. The cell suspension was centrifuged at 5,000 rpm for 5 min at 4°C. Cell pellets were resuspended with 100 μl 1% SDS in presence of a Halt protease inhibitor cocktail and 0.5 M EDTA solution (Thermo Fisher) and cells lysed mechanically by scratching. Protein concentrations were measured using a BCA protein assay kit (23235#, Pierce Company). For detection of the MUC1 ED, 5% mucin gels and a boric acid-Tris system were used as described previously 45 . α-MUC1-ED antibody 214D4 was used to detect MUC1 at a dilution of 1:1,000 in TSMT buffer. For detection of the CT of MUC1, 12% SDS-PAGE gel and α-MUC1-CT antibody CT2 was used. For ACE2 detection, 10% SDS-PAGE gel and anti-ACE2 antibody (1:1,000, HPA000288, Sigma-Aldrich) was used. Actin was detected using α-actin antibody (1:5,000; bs-0061R, Bioss). Secondary antibodies used were α-mouse IgG secondary antibody (1:10,000; A2304, Sigma), α-Armenian hamster IgG (1:10,000; GTX25745, Genetex) and α-rabbit IgG (1:10,000; A4914, Sigma). Blots were developed with the Clarity Western ECL kit (Bio-Rad) and imaged in a Gel-Doc system (Bio-Rad).

For all experiments, at least three independent biological replicates were performed. Values are 

The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century

The molecular virology of coronaviruses

Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

The frontline defence of the lung

Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family

Defensive properties of mucin glycoproteins during respiratory infections-relevance for Sars-CoV-2

Structure and Function of the Cell Surface (Tethered) Mucins

Signaling Receptors at the Intersection of Inflammation and Cancer

MUC1 mucin is a negative regulator of toll-like receptor signaling

Anti-inflammatory effect of MUC1 during respiratory syncytial virus infection of lung epithelial cells in vitro

The cell surface mucin MUC1 limits the severity of influenza A virus infection

A single-cell atlas of the human healthy airways

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

SARS-CoV-2 cellular tropism

An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins

The transmembrane mucin muc1 facilitates b1-integrin-mediated bacterial invasion

Glycan Processing on SARS-CoV-2 Recognition

Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target Cells

Chapter 3 Interactions Between Heparan Sulfate and Proteins-Design and Functional Implications

Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients

The Muc5B Promotor Polymorphism Associates With Severe Covid-19

The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia

Genome-wide, bidirectional CRISPR screens identify mucins as critical host factors modulating SARS-CoV-2 infection

Mucin 4 Protects Female Mice from Coronavirus Pathogenesis

Mucin signature as a potential tool to predict susceptibility to COVID-19

Glycocalyx crowding with mucin mimetics strengthens binding of soluble and virus-associated lectins to host cell glycan receptors

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Sialic acid-Dependent Binding and Viral Entry of SARS-CoV-2

Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro

Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2

Host and viral determinants for efficient SARS-CoV-2 infection of the human lung

Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients

Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome

Epidemiological studies in mucus hypersecretion

Strategies for the prevention and management of coronavirus disease 2019

A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury

Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19

Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury

Integrating single-cell transcriptomic data across different conditions, technologies, and species

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Human airway cells prevent sars-cov-2 multibasic cleavage site cell culture adaptation

MUC1 is a receptor for the Salmonella SiiE adhesin that enables apical invasion into enterocytes

Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

Fiji -an Open platform for biological image analysis

Immunofluorescence confocal microscopy imaging for α-2,6 sialic acids (SNA, red), α-2,3 sialic acids (MALII, red) and fucose (UEA1, red) in combination with MUC1 (214D4 antibody, green) demonstrates high levels of sialic acid and fucose in Calu-3 cells

Infection was not blocked by the anti-spike mAb. (E) Infection of Calu-3 cells with authentic SARS-CoV-2 after treatment with indicated enzymes. StcE treatment resulted in a 2-fold increase in infected cell count. Neuraminidase and fucosidase treatment did not significantly impact viral entry. Represented values are the mean ± SEM of three biological replicates performed in triplicate. Statistical analysis was performed by repeated measures one way-ANOVA with Dunnett's post-hoc test

G) Immunofluorescence confocal microscopy for localization and distribution of ACE2 (green) and TM mucin MUC1 (214D4, red) in Calu-3 cells. For ACE2, a general punctated pattern was observed with the occasional appearance of dome-like structures that were overlayed by MUC1. (H) Immunofluorescence confocal microscopy imaging of Calu-3 cells treated with mucinase and incubated with SARS2-S pseudotyped VSV-GFP (green) for 18-20 h stained with anti-MUC1 214D4 antibody (red) and DAPI (blue)

We thank Wentao Li and Arno van Vliet for assistance in virus production. We thank Robert P. de Vries 

We declare no conflict of interest.

Contact Karin Strijbis (K.Strijbis@uu.nl) for requests and correspondence.